1. India Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Supriya Lifescience Limited

Supriya Lifescience Limited

SUPRIYA.BO
Supriya Lifescience LimitedIN flagBombay Stock Exchange
901.75
INR
-15.15
- -
72.58BMarket Cap
Supriya Lifescience Limited
SUPRIYA.BO
(Bombay Stock Exchange)

Recent

price

901.75

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
108.75
121.99
150.84
64.53
56.04
69.26
86.52
102.85
102.85
Revenue per Share
15.43
28.73
48.38
18.86
11.16
14.8
23.35
25.98
25.98
Basic EPS, GAAP
16.33
35.83
10.82
-1.38
-5.5
-4.02
0.29
4.17
- -
Free Cash Flow per Basic Share
- -
6.91
1.55
0.55
0.6
0.6
0.8
1
- -
Dividend per Share
36.71
58.4
105.04
51.84
62.41
76.61
99.14
2
2
Book Value per Share
35.93
57.15
104.5
76.31
86.78
101.1
123.65
148.64
148.63
Tangible Book Value per Share
26
26
26
80
80
80
80
80
80
Basic Weighted Avg Shares
2,778
3,116
3,854
5,194
4,510
5,574
6,965
8,279
8,279
Sales/Revenue/Turnover
23.42
32.34
42.67
38.92
25.57
28.3
34.51
32.09
32.09
Operating Margin (%)
54
64
68
101
118
158
204
284
284
Depreciation Expense
394
734
1,236
1,518
899
1,191
1,880
2,091
2,091
Net Income, GAAP
30.96
23.72
26.13
26.75
27.23
28.11
24.36
23.9
23.89
Effective Tax Rate (%)
14.19
23.55
32.07
29.23
19.92
21.37
26.99
25.26
25.26
Profit Margin (%)
-20
426
1,194
3,978
3,691
3,209
3,549
4,113
4,113
Working Capital
107
47
21
53
55
50
51
52
52
LT Debt
938
1,492
2,686
6,157
6,995
8,154
9,968
11,977
11,977
Total Equity
- -
36.16
40.13
29.09
12.22
14.7
20.04
18.38
18.38
Return on Invested Capital (%)
- -
37.45
43.79
39.19
18.79
21.24
26.55
51.05
51.05
Return on Capital (%)
- -
60.42
59.2
44.29
19.54
21.29
26.57
51.37
51.37
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
3
- -
2
LT Borrowings
- -
- -
- -
LT Finance Leases
49
- -
52
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
80
- -
80
Market Capitalization
58,550
60,302
45,487

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
5,051
- -
5,323
Cash, Cash Equivalents & STI
1,062
- -
789
Accounts Receivable, Net
1,551
- -
2,194
Inventories
1,428
- -
1,596
Total Current Liabilities
829
- -
1,210
Payables & Accruals
- -
- -
- -
ST Debt
3
- -
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
40.37%
20.16%
Free Cash Flow
- -
276.68%
1,358.63%
Net Income, GAAP
- -
16.73%
11.26%
Sales/Revenue/Turnover
- -
17.8%
18.86%
Total Cash Common Dividend
- -
- -
24.99%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,320
1,401
1,401
1,452
5,574
2025
1,606
1,661
1,856
1,841
6,965
2026
1,451
1,998
2,064
2,765
8,279

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3.54
2.97
3.7
- -
14.8
2025
5.54
5.71
5.82
6.29
23.35
2026
4.32
6.27
6.17
9.22
25.98

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.6
2025
- -
- -
- -
- -
0.8
2026
- -
- -
- -
- -
1
Similar Companies
KALA BIO, Inc. (KALA)
Virpax Pharmaceuticals, Inc. (VRPX)
Septerna, Inc. (SEPN)
Alumis Inc. Common Stock (ALMS)
Xeno Transplants Corporation (XENO)
RespireRx Pharmaceuticals Inc. (RSPI)
Business
Supriya Lifescience Limited is dedicated to the research, development, production, and worldwide distribution of active pharmaceutical ingredients and specialty chemicals. The company offers a diverse range of products spanning multiple therapeutic areas, including antihistamines, antiasthmatics, decongestants, analgesics, anesthetics, and essential vitamins. With a robust portfolio of over 38 specialized APIs, including 15 backward-integrated products, it serves a global customer base across more than 120 countries, with a significant portion of its revenue derived from exports to regulated markets like Europe and Asia. Established in Mumbai, India, in 1987, and incorporated as a public limited company in 2008, Supriya Lifescience operates state-of-the-art manufacturing facilities with international regulatory approvals, emphasizing backward integration for supply chain control and cost efficiency. Recent developments include the inauguration of a new production block (Module E) in late 2024 to expand capacity and support new product launches, such as a recent anesthetic API. The company is also strategically expanding into Contract Development and Manufacturing (CDMO) services, contrast media, and nutraceuticals, targeting substantial future growth.